Health Condition 1: K580- Irritable bowel syndrome with diarrhea
Conditions
Interventions
Intervention1: MetBroma: Test product: Bromelain
Manufactured and marketed by:Meteoric Biopharmaceuticals Private Limited
Mode of usage:Take one capsule twice a day, after meal.
Dosage Form: Capsule
Sponsors
Meteoric Biopharmaceuticals Pvt. Ltd.
Eligibility
Inclusion criteria
Inclusion criteria: 1.The subject is an adult male or female aged between 18 to 60 years old. 2.Clinically diagnosed with irritable bowel syndrome (IBS) based on Rome IV criteria: Abdominal pain at least 4 days per month – over at least 2 months – associated with one or more of the following: i.Related to defecation ii.A change in frequency of stool iii.A change in form (appearance) of stool iv.After appropriate evaluation, the symptoms cannot be fully explained by another medical condition 3.The subject is having refrigerator at their home for storage of test treatment. 4.The subject is willing to provide written informed consent, comply with the study procedures, and be present for all the visits. 5.The subject is willing to abstain from using any other treatments for irritable bowel syndrome during the study period, unless for a medical urgency. 6.The subject is in a stable medical condition, not requiring immediate intervention or hospitalization. 7.If the subject is female, she is willing to use a highly effective method of contraception throughout the clinical investigation. i.Females of childbearing potential must practice and maintain an established method of birth control (e.g., IUD, hormonal implant device/injection, birth control pills, diaphragm, condoms with spermicide, partner vasectomy, or abstinence). ii.Non-childbearing potential females who are surgically sterile, post-menopausal for at least 1 year, or have had a tubal ligation, must have been using hormonal contraception for at least 6 months and agree to continue using the same contraception for the study duration.
Exclusion criteria
Exclusion criteria: 1.The subject has a history of diagnosis of either hypertension, diabetes, or liver disease 2.The subject has any other significant medical condition that could interfere with the study or pose a risk to the participant 3.The subject has used medications that could influence the study outcomes, such as antibiotics, immunosuppressive drugs, and probiotics or prebiotics supplements within the last 4 weeks. 4.The subject works in frequent night shifts (working night shifts at least 3 times per week), and refuses to change the lifestyle. 5.The subject has a history of alcohol abuse 6.The subject is either pregnant, lactating, or plans on conceiving during the course of the study. 7.The subject has participated in other clinical studies or received any investigational agent in the previous 30 days. 8.The subject has other significant gastrointestinal diseases (e.g., Crohn’s disease, ulcerative colitis, celiac disease). 9.The subject has any condition that, in the investigator judgment, would compromise the subject safety or study integrity. 10.The subject has abnormal baseline Haemoglobin, Complete Blood Count, Urine Routine/Microscopy, or Stool Routine/Microscopy results that suggest a different pathology than irritable bowel syndrome.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Evaluate the effect of the test treatment in terms of change in Albumin/Globulin ratio, total serum protein and prealbumin levels. 2.Evaluate the effect of the test treatment in terms of change in the lifestyle using the Scoring and Gradation for assessment of Lifestyle. 3.Evaluate of the effect of test treatment using Scoring and Gradation of symptoms of irritable bowel syndrome Timepoint: Day 01 for baseline, and post-dose on Day 30. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Evaluate the safety of test treatment through the performance of safety laboratory tests including Complete Blood Count (CBC), Biochemical tests, and UrinalysisTimepoint: Day 01 for baseline, and post-dose on Day 30.;Evaluate the effect of the test treatment in terms of change in CRP and IL-6 levels.Timepoint: Assessment of the effectiveness of the test treatment in terms of change in CRP and IL-6 levels on Day 01 (before administration) for baseline, and post-dose on Day 30. | — |
Countries
India
Contacts
Public ContactMaheshvari Patel
NovoBliss Research Private Limited
Outcome results
None listed